Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC.TMCI · Entity 5943 | SVP, Operations | March 08, 2022 | March 11, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TREACE MEDICAL CONCEPTS, INC.
Report date March 08, 2022 · Filed March 11, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,850 |
Last balance in matching sequence
After 2022-03-08 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2022-03-08 · Grant · Acquired 3,350 · Balance 3,350 F1: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in equal annual installments over 4 years, commencing on March 8, 2023 with the last installment on March 8, 2026? subject to Reporting Person's providing continued service to Issuer through each vesting date. F2: Includes 3,350 RSUs. Row 2 · 2022-03-08 · Purchase · Acquired 2,500 · Balance 5,850 F3: The price reported in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $18.347 to $18.65 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: Includes 3,350 RSUs. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.15 · Expires 2032-03-08 | Direct | 25,800 |
Reported balance
After 2022-03-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-08 · Grant · Acquired 25,800 · Balance 25,800 F4: The stock option will vest in equal annual installments over 4 years, commencing on March 8, 2023 with the last installment on March 8, 2026; subject to Reporting Person's providing continued service to Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in equal annual installments over 4 years, commencing on March 8, 2023 with the last installment on March 8, 2026? subject to Reporting Person's providing continued service to Issuer through each vesting date.
F2: Includes 3,350 RSUs.
F3: The price reported in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $18.347 to $18.65 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F4: The stock option will vest in equal annual installments over 4 years, commencing on March 8, 2023 with the last installment on March 8, 2026; subject to Reporting Person's providing continued service to Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 08, 2022 Filed Mar 11, 2022 01:26 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantStock Option (Right to Buy) · Derivative | 25,800 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001567619-22-006732 · doc1.xml · derivative · entry 3 Lubben Terry W. · CIK 0001882643 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,800 Underlying: Common Stock · 25,800 shares Expires 2032-03-08 F4 · derivative.exercise_date: The stock option will vest in equal annual installments over 4 years, commencing on March 8, 2023 with the last installment on March 8, 2026; subject to Reporting Person's providing continued service to Issuer through each vesting date. Read SEC document |
| March 08, 2022 Filed Mar 11, 2022 01:26 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 2,500 | $18.62 | $46,549.75 |
DisclosureSEC source: 0001567619-22-006732 · doc1.xml · nonDerivative · entry 2 Lubben Terry W. · CIK 0001882643 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,850 F3 · price: The price reported in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $18.347 to $18.65 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 3,350 RSUs. Read SEC document |
| March 08, 2022 Filed Mar 11, 2022 01:26 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 3,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-006732 · doc1.xml · nonDerivative · entry 1 Lubben Terry W. · CIK 0001882643 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,350 F1 · shares: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in equal annual installments over 4 years, commencing on March 8, 2023 with the last installment on March 8, 2026? subject to Reporting Person's providing continued service to Issuer through each vesting date. F2 · balance_after: Includes 3,350 RSUs. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 20:14 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantStock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $28.98 | $0.00 |
DisclosureSEC source: 0001567619-21-017391 · doc1.xml · derivative · entry 1 Lubben Terry W. · CIK 0001882643 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2031-09-17 F1 · derivative.exercise_date: The stock option will vest in equal annual installments over 4 years, commencing on September 17, 2022, with the last installment on September 17, 2025 subject to Reporting Person's providing continued service to Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.